Casopitant
As of the edition of 20 October 2026, Casopitant is a small molecule: went quiet in 2009; acts on TACR1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2009
- Kind
- Small molecule
- Registered trials
- 29, 2 stopped early
- Disease areas
- Mental health; Nervous system; Pregnancy and women's health; Urinary and reproductive; Bones, joints and muscles; Cancer
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Casopitant.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TACR1 | Substance-P receptor | P25103 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 11 | 10 | 0 | 1 |
| Phase 2 | 12 | 11 | 0 | 1 |
| Phase 3 | 5 | 5 | 0 | 0 |
| All trials | 29 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| GSK | Lead sponsor of trials | 2004 to now |